GT Biopharma Upsizes Private Placement to $7.75M, Adds New Purchaser

summarizeSummary

GT Biopharma upsized its private placement of Series M convertible preferred stock from $7.45M to $7.75M and added a new purchaser, Nicholas Nikolov, via a joinder agreement.

check_boxKey Events · Financing and Capital Events · GTBP

• Private Placement Upsized to $7.75M

  First Amendment to Securities Purchase Agreement increased the aggregate purchase price from $7.45M to $7.75M, with stated value rising from $8,277,778 to $8,611,111.11.

• New Purchaser Added

  Nicholas R. Nikolov joined as a purchaser via joinder to the Securities Purchase Agreement and Registration Rights Agreement, alongside existing purchasers Five Narrow Lane and Bristol Investment Fund.

• Greenshoe Option Increased

  Greenshoe Rights increased from $30M to $31,208,054 aggregate purchase price (stated value up to $34,675,615), exercisable at each purchaser's pro rata share.

• Series M Preferred Shares Increased

  Certificate of Increase raised designated Series M 10% Convertible Preferred Stock from 41,778 to 43,287 shares, with all other terms unchanged.

auto_awesomeAnalysis · GTBP · Life Sciences

GT Biopharma amended its September 14 securities purchase agreement to increase the offering from $7.45M to $7.75M and add a new purchaser, Nicholas Nikolov. The Greenshoe option also grew from $30M to $31.2M. This is a material delta from the prior 8-K — more capital raised and a new investor brought in — but the terms remain the same convertible preferred structure with warrants. For a company with a ~$13M market cap and going-concern doubts, this incremental capital is meaningful for runway, though the dilution mechanics are unchanged.